VEGZELMA 25 mg/mL concentrate for solution for infusion, DS-8201a
DS8201-772
Phase 3 small_molecule active
Quick answer
VEGZELMA 25 mg/mL concentrate for solution for infusion, DS-8201a for Ovarian Cancer is a Phase 3 program (small_molecule) at Daiichi Sankyo Europe GmbH with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Daiichi Sankyo Europe GmbH
- Indication
- Ovarian Cancer
- Phase
- Phase 3
- Modality
- small_molecule
- Status
- active